Open AccessTreatment of DM2 to-day. Should we change priorities? Conclusions based on recent clinical studies
Author(s) -
Alexey Zilov
Publication year - 2009
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-5716
Subject(s) - medicine , glibenclamide , hypoglycemia , myocardial infarction , incidence (geometry) , cardiology , intensive care medicine , diabetes mellitus , endocrinology , physics , optics
This work is devoted to the analysis of results of recent clinical studies. It is argued that the absence of close association between normalized glycemiaand reduced incidence of cardiovascular disorders may be due to both relatively short duration of observations and possible effect of co-factors (e.g. hypoglycemia/drug interaction, etc.). Some results suggest the necessity of multifactor approach to the treatment of DM2 especially for the reductionof cardiovascular mortality or prevention of vascular catastrophes. Sulphonylurea derivatives are regarded as putative risk factors of hypoglycemiaor vascular disorders. A number of publications are reviewed in which glibenclamide was shown to be safe in terms of risk of myocardial infarction.